Table 1.
Demographics and outcomes n (%)
| Variable | All sample (n = 319) | PyVAN negative (n = 272) | PyVAN positive (n = 47) |
| Age (mean, yr) | 53 | 51 | 53.1 |
| Male | 210 (65.8) | 177 (65.1) | 33 (70.2) |
| Black | 86 (27.0) | 67 (24.6) | 19 (40.4) |
| Diabetes mellitus | 86 (27.0) | 71 (26.1) | 15 (32.0) |
| CMV D+/R- | 58 (18.2) | 49 (18.0) | 9 (19.1) |
| DDKT | 174 (54.5) | 140 (51.5) | 34 (72.3) |
| Induction immunosuppression | |||
| Thymoglobulin | 118 (37.0) | 97 (35.7) | 21 (44.7) |
| Basiliximab | 143 (44.8) | 124 (45.6) | 19 (40.4) |
| Daclizumab | 56 (17.6) | 50 (18.4) | 6 (12.8) |
| Delayed graft function | 58 (18.2) | 47 (17.3) | 11 (23.4) |
| Acute rejection | 59 (18.5) | 44 (16.2) | 15 (32.0) |
| Graft loss | 17 (5.3) | 13 (4.8) | 4 (8.5) |
| Death | 21 (6.6) | 15 (5.5) | 6 (12.8) |
DDKT: Deceased-donor kidney transplantation; PyVAN: Polyoma-virus associated nephropathy.